

Indra N Guha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5717324/publications.pdf>

Version: 2024-02-01

92
papers

5,350
citations

117571

34
h-index

88593

70
g-index

93
all docs

93
docs citations

93
times ranked

6591
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic variation in <i>TERT</i> modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. <i>Gut</i> , 2023, 72, 381-391.	6.1	19
2	Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity. <i>Hepatology</i> , 2022, 75, 369-378.	3.6	12
3	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. <i>Hepatology</i> , 2022, 75, 219-228.	3.6	107
4	Health Technology Adoption in Liver Disease: Innovative Use of Data Science Solutions for Early Disease Detection. <i>Frontiers in Digital Health</i> , 2022, 4, 737729.	1.5	3
5	Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-stratification in Patients with Hepatitis C Cirrhosis.. <i>Clinical and Translational Gastroenterology</i> , 2022, Publish Ahead of Print, .	1.3	2
6	Transient Elastography in Community Alcohol Services: Can It Detect Significant Liver Disease and Impact Drinking Behaviour?. <i>Biomedicines</i> , 2022, 10, 477.	1.4	4
7	Performance of routine risk scores for predicting cirrhosis-related morbidity in the community. <i>Journal of Hepatology</i> , 2022, 77, 365-376.	1.8	20
8	Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2567-2576.e6.	2.4	80
9	The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1213-1226.	2.0	9
10	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1248-1257.	2.4	25
11	Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes Study. <i>Obesity Science and Practice</i> , 2021, 7, 497-508.	1.0	2
12	Reliable computational quantification of liver fibrosis is compromised by inherent staining variation. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 471-481.	1.3	8
13	Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. <i>JHEP Reports</i> , 2021, 3, 100384.	2.6	10
14	Validation of the AASLD recommendations for classification of oesophageal varices in clinical practice. <i>Liver International</i> , 2020, 40, 905-912.	1.9	10
15	Editorial: blood biomarkers for advanced liver fibrosis in non-alcoholic fatty liver disease—“not a simple choice?”. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 179-180.	1.9	1
16	Health related quality of life in individuals at high risk of chronic liver disease: Impact of a community diagnostic pathway. <i>Public Health in Practice</i> , 2020, 1, 100033.	0.7	4
17	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020, 73, 1368-1378.	1.8	158
18	Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community. <i>Frontline Gastroenterology</i> , 2020, 11, 86-92.	0.9	45

#	ARTICLE	IF	CITATIONS
19	Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. <i>Gastroenterology</i> , 2020, 159, 1276-1289.e7.	0.6	53
20	Noninvasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study. <i>Liver International</i> , 2020, 40, 2252-2262.	1.9	14
21	Detecting chronic liver disease: are liver function tests the solution?. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2020, 81, 1-8.	0.2	2
22	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 362-373.	3.7	411
23	Acceptability of chronic liver disease screening in a UK primary care setting: a qualitative evaluation. <i>BMJ Open</i> , 2020, 10, e041574.	0.8	5
24	ADAPT: An Algorithm Incorporating PRO3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. <i>Hepatology</i> , 2019, 69, 1075-1086.	3.6	174
25	SAT-032-Spleen to liver stiffness ratio significantly differs between ALD and HCV and predicts disease specific complications. <i>Journal of Hepatology</i> , 2019, 70, e640.	1.8	0
26	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. <i>Journal of Hepatology</i> , 2019, 71, 1141-1151.	1.8	104
27	Time to endoscopy for acute upper gastrointestinal bleeding: Results from a prospective multicentre trainee-led audit. <i>United European Gastroenterology Journal</i> , 2019, 7, 199-209.	1.6	25
28	A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2019, 22, 693-703.	0.1	13
29	Validation of a Model for Identification of Patients With Compensated Cirrhosis at High Risk of Decompensation. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2330-2338.e1.	2.4	39
30	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2019, 156, 1717-1730.	0.6	777
31	Acceptability to patients of screening disposable transnasal endoscopy: qualitative interview analysis. <i>BMJ Open</i> , 2019, 9, e030467.	0.8	8
32	Obesity Is the Most Common Risk Factor for Chronic Liver Disease: Results From a Risk Stratification Pathway Using Transient Elastography. <i>American Journal of Gastroenterology</i> , 2019, 114, 1744-1752.	0.2	32
33	Acceptability, Accuracy, and Safety of Disposable Transnasal Capsule Endoscopy for Barrett's Esophagus Screening. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 638-646.e1.	2.4	30
34	The effects of terlipressin and direct portacaval shunting on liver hemodynamics following 80% hepatectomy in the pig. <i>Clinical Science</i> , 2019, 133, 153-166.	1.8	7
35	Using MRI to study the alterations in liver blood flow, perfusion, and oxygenation in response to physiological stress challenges: Meal, hyperoxia, and hypercapnia. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 1577-1586.	1.9	10
36	Short-term changes observed in multiparametric liver MRI following therapy with direct-acting antivirals in chronic hepatitis C virus patients. <i>European Radiology</i> , 2019, 29, 3100-3107.	2.3	11

#	ARTICLE	IF	CITATIONS
37	Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease. <i>Histopathology</i> , 2018, 73, 90-100.	1.6	13
38	Analysis of genotyping for predicting liver injury marker, procollagen $\alpha 1(I)$ in persons at risk of non-alcoholic fatty liver disease. <i>Liver International</i> , 2018, 38, 1832-1838.	1.9	2
39	Algorithm to identify patients with an activity grade ≥ 2 in type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD)-development in a large prospective multicenter UK study. <i>Journal of Hepatology</i> , 2018, 68, S552-S553.	1.8	1
40	Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 504-515.	1.9	49
41	Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 25-36.	3.7	113
42	Transient elastography can stratify patients with Child-Pugh A cirrhosis according to risk of early decompensation. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1434-1440.	0.8	7
43	MRI assessment of altered dynamic changes in liver haemodynamics following a meal challenge in compensated cirrhosis. <i>European Radiology Experimental</i> , 2018, 2, .	1.7	6
44	SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis. <i>Scientific Reports</i> , 2018, 8, 17905.	1.6	30
45	The XL probe: A luxury or a necessity? Risk stratification in an obese community cohort using transient elastography. <i>United European Gastroenterology Journal</i> , 2018, 6, 1372-1379.	1.6	5
46	Performance of controlled attenuation parameter (CAP) to assess steatosis in a large prospective multicentre UK study of patients with non-alcoholic fatty liver disease (NAFLD). <i>Journal of Hepatology</i> , 2018, 68, S98.	1.8	0
47	Magnetic Resonance Imaging Methods for Assessing Cirrhosis and Portal Hypertension. , 2018, , 211-223.		0
48	Non-invasive tests for the detection of oesophageal varices in compensated cirrhosis: systematic review and meta-analysis. <i>United European Gastroenterology Journal</i> , 2018, 6, 806-818.	1.6	13
49	Multi-organ assessment of compensated cirrhosis patients using quantitative magnetic resonance imaging. <i>Journal of Hepatology</i> , 2018, 69, 1015-1024.	1.8	38
50	Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 288-297.	3.7	138
51	$\alpha 1(I)$ predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis. <i>EMBO Molecular Medicine</i> , 2017, 9, 1696-1710.	3.3	38
52	Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. <i>BMJ Open</i> , 2017, 7, e015659.	0.8	50
53	Visual morphometry and three non-invasive markers in the evaluation of liver fibrosis in chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 107-115.	0.6	15
54	The effect of prone positioning with surgical bolsters on liver blood flow in healthy volunteers. <i>Anaesthesia</i> , 2016, 71, 550-555.	1.8	11

#	ARTICLE	IF	CITATIONS
55	Screening for liver fibrosis in the general population: a call for action. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 256-260.	3.7	131
56	Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging. <i>Journal of Hepatology</i> , 2016, 65, 1131-1139.	1.8	87
57	Biomarkers of liver fibrosis. <i>Clinical Liver Disease</i> , 2016, 7, 139-142.	1.0	7
58	The detection of oesophageal varices using a novel, disposable, probe-based transnasal endoscope: a prospective diagnostic pilot study. <i>Liver International</i> , 2016, 36, 1639-1648.	1.9	10
59	Clinically significant chronic liver disease in people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 249-256.	0.2	12
60	The value of aspartate aminotransferase and alanine aminotransferase in cardiovascular disease risk assessment. <i>Open Heart</i> , 2015, 2, e000272.	0.9	51
61	A study of T_1 relaxation time as a measure of liver fibrosis and the influence of confounding histological factors. <i>NMR in Biomedicine</i> , 2015, 28, 706-714.	1.6	100
62	Tu1529 Superior Patient Preference and High Diagnostic Accuracy for the Detection of Barrett's Esophagus Using a Novel, Portable, Probe-Based TransNasal Endoscope. <i>Gastrointestinal Endoscopy</i> , 2015, 81, AB497-AB498.	0.5	0
63	γ -Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study. <i>Diabetologia</i> , 2015, 58, 1484-1493.	2.9	13
64	REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (G-CSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2015, 5, e007700-e007700.	0.8	28
65	Evaluation of area-based collagen scoring by nonlinear microscopy in chronic hepatitis C-induced liver fibrosis. <i>Biomedical Optics Express</i> , 2015, 6, 1209.	1.5	10
66	Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography. <i>BMJ Open</i> , 2015, 5, e007516-e007516.	0.8	86
67	Performance characteristics of unsedated ultrathin video endoscopy in the assessment of the upper GI tract: systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2015, 82, 782-792.	0.5	48
68	Metabolic Phenotyping for Enhanced Mechanistic Stratification of Chronic Hepatitis C-Induced Liver Fibrosis. <i>American Journal of Gastroenterology</i> , 2015, 110, 159-169.	0.2	29
69	Non-invasive monitoring of liver fibrosis. <i>British Medical Bulletin</i> , 2014, 112, 97-106.	2.7	10
70	Multiplex Protein Analysis to Determine Fibrosis Stage and Progression in Patients With Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2113-2120.e3.	2.4	24
71	Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: The Edinburgh type 2 diabetes study. <i>Journal of Hepatology</i> , 2014, 60, 384-391.	1.8	63
72	Non-invasive hepatic biomarkers (α -FET and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study. <i>Liver International</i> , 2014, 34, 1267-1277.	1.9	7

#	ARTICLE	IF	CITATIONS
73	Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2013, 57, 103-111.	3.6	103
74	Structural and functional uncoupling of liver performance in the Fontan circulation. <i>International Journal of Cardiology</i> , 2013, 164, 77-81.	0.8	38
75	The performance of transient elastography compared to clinical acumen and routine tests – what is the incremental diagnostic value?. <i>Liver International</i> , 2013, 33, 172-179.	1.9	7
76	Were James Bond's drinks shaken because of alcohol induced tremor?. <i>BMJ, The</i> , 2013, 347, f7255-f7255.	3.0	16
77	Economic modelling of early transjugular intrahepatic portosystemic shunt insertion for acute variceal haemorrhage. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 201-207.	0.8	14
78	Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease. <i>Comparative Hepatology</i> , 2012, 11, 5.	0.9	27
79	Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans. <i>Hepatology</i> , 2012, 56, 1108-1116.	3.6	81
80	Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2011, 18, 23-31.	1.0	153
81	Biomarkers of liver fibrosis: What lies beneath the receiver operating characteristic curve?. <i>Hepatology</i> , 2011, 54, 1454-1462.	3.6	48
82	Prediction, prevention and management of postresection liver failure. <i>British Journal of Surgery</i> , 2011, 98, 1188-1200.	0.1	168
83	Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen – following exposure to hepatitis C virus. <i>Hepatology</i> , 2010, 51, 1168-1175.	3.6	145
84	Antibiotic prophylaxis in variceal hemorrhage: Timing, effectiveness and <i>Clostridium difficile</i> rates. <i>World Journal of Gastroenterology</i> , 2010, 16, 5317.	1.4	23
85	Back to the future with noninvasive biomarkers of liver fibrosis. <i>Hepatology</i> , 2009, 49, 9-11.	3.6	6
86	Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. <i>Hepatology</i> , 2008, 47, 455-460.	3.6	625
87	Noninvasive Assessment of Liver Fibrosis: Serum Markers, Imaging, and Other Modalities. <i>Clinics in Liver Disease</i> , 2008, 12, 883-900.	1.0	35
88	Resolving fibrosis in the diseased liver: Translating the scientific promise to the clinic. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 695-714.	1.2	43
89	Performance of serum marker panels for liver fibrosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 2006, 44, 462-474.	1.8	217
90	Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. <i>Gut</i> , 2006, 55, 1650-1660.	6.1	113

#	ARTICLE	IF	CITATIONS
91	Case report of an arterioportal fistula, presenting with accelerated decompensation and sepsis, twenty-six years after initial liver biopsy. Hepatology Research, 2005, 32, 252-255.	1.8	3
92	F2-isoprostanes and the liver. Prostaglandins and Other Lipid Mediators, 2003, 72, 73-84.	1.0	5